Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, ...

Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...

The Delaware Supreme Court appeared skeptical Wednesday of arguments that a trial judge misinterpreted contract language ...

Bullish option flow detected in Teva (TEVA) with 28,557 calls trading, 1.5x expected, and implied vol increasing almost 16 points to 57.61%.

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

Teva Pharmaceutical Industries Limited ( NYSE: TEVA) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief ...

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on January 8. Read why I rate ...

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) and increased ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.94 which represents a decrease of $-0.55 or -2.56% from the prior close of $21.49. The stock opened at $21.27 and ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...